CA
NZ
UK
AU
IND
US
Zevra Therapeutics (NASDAQ:ZVRA) shares gained in pre-market trading Friday, building on investor enthusiasm following management's presentation at the H.C. Wainwright 28th Annual Global Investment Conference this week. Zevra Therapeutics, founded in 2006 as KemPharm and rebranded in February 2023, is a Boston-headquartered commercial-stage biopharmaceutical …
Aethlon Medical (NASDAQ:AEMD) shares pulled back in pre-market trading Friday, cooling off after Thursday's 374.13% single-session surge on news of a definitive merger agreement with North Immunology, a privately held biotechnology company developing bispecific antibodies for immune and inflammatory diseases. Aethlon Medical is a …
Tempest Therapeutics (Nasdaq: TPST) was the session's biggest gainer, closing up 59% at $1.20 after securing an exclusive option agreement with Senlang for a CD7-targeted lentiviral vector platform and in vivo CAR-T portfolio. The deal adds a Phase 1 BCMA/GPRC5D dual-targeting candidate for multiple …
The move extends strategic momentum from a September 9, 2026 restructuring in which PRF Technologies (Nasdaq: PRFX) established GridFeed as a dedicated corporate unit focused on forming alliances with data center operators. The initiative seeks to give operators enhanced capacity management tools, reduced electricity …
The update follows earlier positive initial efficacy data from Part C of the Phase 2 expansion trial, which evaluated ateganosine followed by cemiplimab in third-line advanced NSCLC. That cohort showed an interim disease control rate of 90.5%, data that had been noted on July …
The new collaboration sits alongside Tiziana Life Sciences' (Nasdaq: TLSA) ongoing, blinded Phase 2 trial in non-active secondary progressive multiple sclerosis, for which a data readout remains on track for October 2026. Together, the two programs broaden the company's multiple sclerosis pipeline across different …
The option agreement is designed to complement Tempest Therapeutics' (Nasdaq: TPST) own CD7-targeted lipid nanoparticle in vivo CAR-T platform, which remains in earlier-stage development. By adding a lentiviral vector approach through Senlang, the company gains a second, potentially more durable route to generating CAR-T …
The combined company will be guided by Santersus Chief Executive Officer James Ladtkow and will carry forward a four-program clinical portfolio centered on neutrophil extracellular traps, or NETs. The pipeline is headlined by two candidates that hold FDA Breakthrough Device designation in pivotal-phase development …
The clinical program is structured in two stages. An initial single-arm Phase 2a cohort will assess safety, followed by a randomized Phase 2b stage evaluating therapeutic efficacy. If NV-387 advances through this pathway, NanoViricides (NYSE: NNVC) said it would represent the only oral therapeutic …
Extended monitoring of the TRUST-I study population revealed no novel safety concerns and required no modifications to the existing safety labeling for IBTROZI, according to Nuvation Bio (NYSE: NUVB).
Please wait processing your request...